Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GC012F Injection
GC012F · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| GC012F | BIOLOGICAL | GC012F is a BCMA/CD19 dual CAR product |
| GC012F Injection | DRUG | The investigational agent, GC012F, is an autologous BCMA/CD19 dual directed CAR product under investigation for the treatment of patients with RRMM, ELMM, SLE, and B NHL. |
Top 20 of 25 competitors
GC012F is an investigational monoclonal antibody being studied for multiple myeloma, refractory systemic lupus erythematosus, and relapsed/refractory AL amyloidosis. It is in clinical development and has not been approved by regulatory authorities.
GC012F is a CAR-T therapy that targets CD19 and BCMA, as described in a clinical trial for relapsed or refractory AL amyloidosis. It is being developed by AstraZeneca PLC (AZN) for oncology and other indications.
AstraZeneca PLC (ticker: AZN) is developing GC012F. The drug is an investigational monoclonal antibody being studied in clinical trials for multiple myeloma, refractory systemic lupus erythematosus, and relapsed/refractory AL amyloidosis.
GC012F is in Phase 2 clinical development overall, with individual trials in Phase 1 and Phase 1/2. It is investigational and not yet approved. Active trials are recruiting for multiple myeloma, lupus, and AL amyloidosis.
GC012F is being studied in three recruiting trials: NCT06235229 for relapsed/refractory multiple myeloma (Phase 1/2, 110 participants), NCT06530849 for refractory systemic lupus erythematosus (Phase 1, 18 participants), and NCT07250269 for relapsed/refractory AL amyloidosis (Phase 1, 9 participants).
Yes, GC012F is also known as GC012F Injection. Both names refer to the same investigational drug being developed by AstraZeneca PLC for multiple myeloma, refractory systemic lupus erythematosus, and relapsed/refractory AL amyloidosis.